Anti-tumour therapeutic efficacy of OX40L in murine tumour model

Ali, S.A., Ahmad, M. ORCID: 0000-0002-6074-2001, Lynam, J., Mclean, C.S., Entwisle, C., Loudon, P., Choolun, E., McArdle, S.E. ORCID: 0000-0001-6929-9782, Li, G., Mian, S. and Rees, R.C. ORCID: 0000-0002-4574-4746, 2004. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine, 22 (2728), pp. 3585-3594. ISSN 0264-410X

Preview

Text 184835_2550 Ali PostPrint.pdf Download (213kB) | Preview

Abstract

OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4+ and CD8+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.

Item Type:	Journal article
Publication Title:	Vaccine
Creators:	Ali, S.A., Ahmad, M., Lynam, J., Mclean, C.S., Entwisle, C., Loudon, P., Choolun, E., McArdle, S.E., Li, G., Mian, S. and Rees, R.C.
Publisher:	Elsevier (not including Cell Press)
Place of Publication:	Oxford
Date:	2004
Volume:	22
Number:	2728
ISSN:	0264-410X
Identifiers:	Number Type 10.1016/j.vaccine.2004.03.041 DOI
Divisions:	Schools > School of Science and Technology
Record created by:	EPrints Services
Date Added:	09 Oct 2015 11:10
Last Modified:	24 Nov 2021 14:27
URI:	https://irep.ntu.ac.uk/id/eprint/23695

Actions (login required)

Edit View

Views

Downloads